Industry

-

Saniona has finalized preclinical development of its KCa3.1 inhibitor SAN903 for the treatment of inflammatory and fibrotic diseases

Source: Saniona

saniona

Industry

-

Saniona reports positive results from the SAN711 Phase 1 clinical trial

Source: Saniona

doctor

Industry

-

Saniona initiates Phase 1 clinical trial of SAN711 for the treatment of rare neuropathic disorders

Source: Saniona

tubes

Industry

-

Saniona regains GABAa5 negative allosteric modulator program from Boehringer Ingelheim

Ion Channel library
About
Credits

artem@ionchannellibrary.com

© 2023 Artem Kondratskyi

Terms of Use

Privacy policy